Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”

Abstract Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications—methadone, buprenorphine, and extended-release injectable naltrexone,— are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited...

Descripción completa

Detalles Bibliográficos

Autores principales:	Matisyahu Shulman, Roger Weiss, John Rotrosen, Patricia Novo, Elizabeth Costello, Edward V. Nunes
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2021-03-01
Colección:	Addiction Science & Clinical Practice
Materias:	Opioid use disorder Buprenorphine Naltrexone Clinical trials
Acceso en línea:	https://doi.org/10.1186/s13722-021-00223-z
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!